Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0282099 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Teerachat Saeheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College, Thammasat University …. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria, Falciparum, Sesquiterpenes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thammasat University, National Research Council of Thailand.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Declining in susceptibility of Plasmodium falciparum to mefloquine is reported in South-East Asia. A revisiting on mefloquine pharmacokinetics-pharmacodynamics (PK/PD) could assist in finding new appropriate dosage regimens in combination with artesunate as a three-day course treatment.
Objective
This study aimed to investigate promising alternative artesunate-mefloquine combination regimens that are effective for the treatment of patients with mefloquine-sensitive and resistant P . falciparum malaria.
Methods
Data collected during 2008–2009 from 124 patients with uncomplicated P . falciparum malaria were included in the analysis, 90 and 34 patients with sensitive and recrudescence response, respectively. All patients were treated with a three-day combination of artesunate-mefloquine. Population PK-PD models were developed. The developed models were validated with clinically observed data. Simulations of clinical efficacy of alternative mefloquine regimens were performed based on mefloquine sensitivity, patients’ adherence and parasite biomass.
Results
The developed PK/PD models well described with clinically observed data. For mefloquine-resistant P . falciparum , a three-day standard regimen of artesunate-mefloquine is suitable (>50% efficacy) only when the level of parasite sensitivity was < 1.5-fold of the cut-off level (IC 50 < 36 nM). For mefloquine-sensitive parasite with IC 50 < 23.19 nM (0.96-fold), all regimens provided satisfactory efficacy. In the isolates with IC 50 of 24 nM, regimen-I is recommended. Curative treatment criteria for mefloquine and artesunate were C 336h (>408 ng.mL -1 ) or C max /IC 50 (>130.1 g.m/M), and C max /IC 50 (>381.2 g.m/M), respectively.
Conclusions
Clinical use of a three-day standard artesunate-mefloquine is suitable only when the IC 50 of P . falciparum isolates is lower than 36 nM. Otherwise, other ACT regimens should be replaced. For mefloquine-sensitive parasite, a dose reduction is recommended with the IC 50 is lower than 23.19 nM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thaila…
- Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand.
ORCID-Profile: Kesara Na-Bangchang
Förderung
- Thammasat University
- National Research Council of Thailand
Zitieren
APA
Saeheng, T., & Na-Bangchang, K. (2023). Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria. PLOS ONE. https://doi.org/10.1371/journal.pone.0282099
Vancouver
Saeheng T, Na-Bangchang K. Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria. PLOS ONE. 2023. doi:10.1371/journal.pone.0282099
BibTeX
@article{Saeheng2023,
author = {Saeheng, Teerachat and Na-Bangchang, Kesara},
title = {Prediction of improved antimalarial chemotherapy of artesunate-mefloquine in combination with mefloquine sensitive and resistant Plasmodium falciparum malaria},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0282099}
}
EUVIMED